Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Production of Antibiotics01:27

Production of Antibiotics

93
Penicillin, one of the earliest and most widely used antibiotics, is produced industrially by the filamentous fungus Penicillium chrysogenum. Large stirred-tank bioreactors ranging from tens to hundreds of thousands of liters maintain tightly controlled temperature, pH, and dissolved oxygen conditions to support fungal metabolism and maximize antibiotic yield. Penicillin is a secondary metabolite, synthesized primarily during the stationary growth phase, which requires a carefully managed...
93
Development of Antibiotic Resistance01:30

Development of Antibiotic Resistance

2.0K
Antibiotic resistance is a major public health concern that arises when bacteria evolve mechanisms to withstand the effects of antibiotic treatments. This resistance can be intrinsic, acquired through genetic mutations, or transferred between bacteria via horizontal gene transfer. The development of antibiotic resistance poses significant challenges in treating bacterial infections and necessitates ongoing research to develop new therapeutic strategies.Intrinsic resistance occurs when bacterial...
2.0K
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

43
Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within...
43
Antibiotic Selection00:57

Antibiotic Selection

62.2K
Overview
62.2K
Preclinical Development: Overview01:28

Preclinical Development: Overview

6.5K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
6.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

5.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
5.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Highly potent quinoxalinediones inhibit α-hemolysin and ameliorate Staphylococcus aureus lung infections.

Cell host & microbe·2025
Same author

Interaction of the Atypical Tetracyclines Chelocardin and Amidochelocardin with Renal Drug Transporters.

ACS pharmacology & translational science·2024
Same author

MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans.

NPJ vaccines·2024
Same author

Pharmacokinetic and pharmacodynamic evaluation of the atypical tetracyclines chelocardin and amidochelocardin in murine infection models.

Microbiology spectrum·2023
Same author

Towards the sustainable discovery and development of new antibiotics.

Nature reviews. Chemistry·2023
Same author

Fighting antibiotic resistance-strategies and (pre)clinical developments to find new antibacterials.

EMBO reports·2022

Related Experiment Video

Updated: Apr 7, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

11.9K

Antibiotics Clinical Development and Pipeline.

Thomas Hesterkamp1

  • 1Helmholtz-Zentrum für Infektionsforschung and Deutsches Zentrum für Infektionsforschung, Inhoffenstraße 7, 38124, Braunschweig, Germany. thomas.hesterkamp@helmholtz-hzi.de.

Current Topics in Microbiology and Immunology
|July 12, 2015
PubMed
Summary

Novel antibiotic development is crucial due to rising resistance. While gram-positive treatments improve, significant unmet needs remain for gram-negative infections, particularly those caused by multidrug-resistant bacteria.

More Related Videos

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.6K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K

Related Experiment Videos

Last Updated: Apr 7, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
10:49

Antibiotic Dereplication Using the Antibiotic Resistance Platform

Published on: October 17, 2019

11.9K
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
11:17

Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses

Published on: August 30, 2018

13.6K
Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments
07:50

Author Spotlight: Scalable Drug Screening Protocol for Efficient Discovery of M. abscessus Treatments

Published on: October 25, 2024

2.5K

Area of Science:

  • Pharmaceuticals
  • Infectious Diseases
  • Drug Development

Background:

  • Antibiotic resistance necessitates novel drug development.
  • Government incentives encourage small/medium biopharma in antibiotic R&D.
  • Major pharmaceutical companies have largely exited the antibiotic development space due to ROI concerns.

Purpose of the Study:

  • To review the clinical pipeline of novel antibiotics.
  • To identify unmet medical needs in antibiotic development.
  • To categorize the pipeline by clinical indication.

Main Methods:

  • Literature review of the clinical antibiotic pipeline.
  • Analysis of approved drugs and ongoing clinical trials.
  • Identification of pathogens and infections with limited treatment options.

Main Results:

  • Improved drug portfolio for gram-positive infections, including methicillin-resistant Staphylococcus aureus.
  • Significant unmet needs in gram-negative infections like complicated intra-abdominal infections, bloodstream infections, hospital-acquired pneumonia, and ventilator-associated pneumonia.
  • Limited options for extended-spectrum beta-lactamase/carbapenemase-producing Enterobacteriaceae and multidrug-resistant non-fermenting gram-negative bacteria (Pseudomonas aeruginosa, Acinetobacter baumannii).

Conclusions:

  • The antibiotic pipeline shows progress for gram-positive pathogens.
  • There is a critical and growing unmet need for novel antibiotics targeting resistant gram-negative pathogens.
  • Further investment and research are essential to address the pipeline gaps for challenging gram-negative bacterial infections.